SAN DIEGO, August 21, 2025 — Leads & Copy — Skye Bioscience, Inc. (Nasdaq: SKYE) will participate in investment and medical conferences. Investment conferences include the Cantor Global Healthcare Conference in New York on Sept. 5, the H.C. Wainwright Global Investment Conference in New York on Sept. 8, and the Morgan Stanley Global Healthcare Conference in New York on Sept. 10. Medical/Scientific conferences include Obesity Science & Innovation in Boston on Sept. 16 and the European Association for the Study of Diabetes Annual Meeting (EASD) in Vienna, Austria, on Sept. 19.
Skye is focused on unlocking new therapeutic pathways for metabolic health through the development of next-generation molecules that modulate G-protein coupled receptors. Skye is conducting a Phase 2a clinical trial in obesity for nimacimab, a negative allosteric modulating antibody that peripherally inhibits CB1.
Investor Relations:
ir@skyebioscience.com
(858) 410-0266
LifeSci Advisors, Mike Moyer
mmoyer@lifesciadvisors.com
(617) 308-4306
Media Inquiries:
LifeSci Communications, Michael Fitzhugh
mfitzhugh@lifescicomms.com
(628) 234-3889
Source: Skye Bioscience
